Document is current
Any future updates will be listed below
-
Authors
Ott, Patrick A. https://orcid.org/0000-0002-4253-943X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (R01 CA229261)
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 19 January 2026
First Online: 10 March 2026
Competing interests
: P.A.O. has received research funding from, and/or has advised, Agenus, Arcturus, Amgen, Armo BioSciences, Array, AstraZeneca/MedImmune, Bristol Myers Squibb, Celldex, CytomX, Evaxion, Immunetune, Imunon, LG Chem, Merck, Moderna, Neon Therapeutics (now BioNTech US), Novartis, PharmaJet, Phio, Pfizer, Oncorus, Roche/Genentech, Servier and Xencor.
